AbbVie: above expectations in the 2nd quarter.
(CercleFinance.com) - Published this Friday before the stock markets opened, the accounts for AbbVie's second quarter have been revealed to be slightly above analysts' expectations.
They are characterised by earnings per share (EPS) of 1.19 dollars, up 21 cents compared to the second quarter of 2016. Outside exceptional items, the pharmaceutical research specialist's EPS came out at 1.42 dollars, or 2 cents more than consensus.
Revenue went from 6.45 billion to 6.94 billion dollars, whereas the market expectation was 6.93 billion.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
They are characterised by earnings per share (EPS) of 1.19 dollars, up 21 cents compared to the second quarter of 2016. Outside exceptional items, the pharmaceutical research specialist's EPS came out at 1.42 dollars, or 2 cents more than consensus.
Revenue went from 6.45 billion to 6.94 billion dollars, whereas the market expectation was 6.93 billion.
Copyright (c) 2017 CercleFinance.com. All rights reserved.